NCT07054489Recruiting
UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF
Using Polygenic Scores to Guide Beta-blocker Therapy for Heart Failure With Mildly Reduced Ejection Fraction
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
This study will use polygenic scores, a tool which describes differences in genetics, to examine effectiveness of beta blocker medication in heart failure patients with ejection fraction of 41-50 percent. The study will also assess beta blockers' effect on the changes in left ventricular end-systolic volume index by MRI.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 24 Mar 2025
- Start date
- 30 Mar 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- David Lanfear
- Diseases
- Heart failure
- NCT number
- NCT07054489
What you commit to
- Study type: Interventional
- Planned participants: 10
- From 30 Mar 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous documented EF =\< 35%
- Currently on BB =\>25% target dose
- MI/ PCI or other cardiac surgery within 90 days prior to enrollment or planned in the future
Other illness
- Uncontrolled hypertension (systolic BP \> 180 at enrollment)
- Systolic BP \< 100 or heart rate \<70
- Current cancer requiring active treatment
- Heart transplant or LVAD or expected in the next year
- Absolute indication for BB other than heart failure (e.g. tachyarrhythmia required BB for rate control, angina)
Other
- Unable to provide informed consent
- Has contraindications to all BB or intolerance to metoprolol
- Life expectancy \< 1 year for any reason
- Dialysis dependence or ESRD
- If PI decides for any reason participation in trial is not in best interest of the patient
- Has a contraindication to completing MRI procedures
Who the study is looking for
- Age 18-89 years
- Ejection Fraction (EF) \>40% and =\<50% by any modality within 1 year (must be most recent)
- Clinical diagnosis of HF within 1 year, evidenced by any one: Hospital discharge with primary or secondary HF diagnosis, ER discharge with primary diagnosis of HF, ambulatory diagnostic code for HF and diuretic use, BNP\>35 ng/L or NTproBNP \>125 ng/L at any time
- Expected ability to fully participate in study (can tolerate study processes, no long travel)
Age in the registry: 18 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Henry Ford Health Coordinator of this site? Confirm its status | Detroit | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.